Peptide Schedule
Pinealon3 residuesEDREach bubble = one amino acid. Size = residue mass. Color = chemical class.Pinealon
Benefits
About Pinealon
Pinealon is a synthetic tripeptide bioregulator composed of L-glutamic acid, L-aspartic acid, and L-arginine (Glu-Asp-Arg, or EDR). Developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it belongs to the cytomedins — short peptides derived from tissue-specific extracts. Pinealon is proposed to target the pineal gland and central nervous system, with preclinical studies suggesting it may cross the blood-brain barrier and interact directly with chromatin to influence gene expression. Animal and in vitro research has linked EDR to increased neuronal viability, reduced apoptosis, and modulation of BDNF and antioxidant pathways. However, the evidence base is narrow: most studies originate from a single research group, many are published only in Russian, and no controlled human clinical trials have been completed. Claims around sleep quality, circadian rhythm correction, and cognitive enhancement remain preliminary. Users should treat Pinealon as an experimental compound with significant evidence gaps.
Who Should Consider Pinealon
- Adults over 40 experiencing age-related cognitive decline
- Individuals with disrupted sleep-wake cycles or shift workers
- Researchers studying bioregulator peptides and epigenetic gene regulation
- Those interested in neuroprotective strategies (preclinical evidence only)
How Pinealon Works
Pinealon (EDR) is a tripeptide originally isolated from the neuroprotective polypeptide drug Cortexin. Fluorescence-labeled studies show it can translocate to the cell nucleus, where it interacts with DNA promoter regions and chromatin-associated proteins to influence gene transcription. It has been shown to upregulate BDNF, modulate the Bcl-2/Bax ratio to reduce apoptosis, activate PGC-1α for mitochondrial biogenesis, and increase histone acetylation at neuronal gene loci. It also modulates the MAPK/ERK signaling pathway and expression of antioxidant enzymes (SOD2, GPX1). Its proposed effect on circadian rhythm is attributed to epigenetic regulation of pineal gland function rather than direct melatonin supplementation.
What to Expect
Some users report improved sleep onset and subjective sleep quality. These early reports are anecdotal and may reflect placebo response.
Possible improvement in circadian rhythm regularity and morning alertness. Still too early for measurable cognitive effects.
Anecdotal reports of enhanced memory and focus. Neuroprotective effects, if real, would be accumulating at the cellular level but are not directly perceptible. End of standard on-cycle.
Bioregulator theory suggests effects persist after discontinuation as gene expression changes stabilize. This claim lacks controlled human data.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | Daily |
Note: Tripeptide bioregulator (Glu-Asp-Arg). Targets pineal gland and CNS. Dose in the evening. Oral capsules also available. Very limited human PK data — dosing based on Russian bioregulator protocols.
How to Inject Pinealon
For subcutaneous use, inject in the evening approximately 1-2 hours before sleep. For oral capsules, take with a small amount of healthy fat to support absorption. Avoid caffeine within 6 hours of dosing. Rotate injection sites if using subcutaneous route.
Cycling Protocol
Standard Russian bioregulator cycling protocol. The long off-period is intended to allow endogenous regulatory mechanisms to re-establish. Limited data on optimal cycling.
Pharmacokinetics
Source: Estimated from tripeptide class pharmacokinetics; no direct PK study for EDR. Small peptides are rapidly cleared (minutes).
Loading the interactive decay curve.
Side Effects
Generally reported as well-tolerated in limited studies. Vivid dreams are commonly noted anecdotally. Rare mild headache. No serious adverse events documented, though the safety dataset is very small and lacks controlled trial data.
Contraindications
- Pregnancy or breastfeeding (no safety data)
- Known hypersensitivity to any component (glutamic acid, aspartic acid, arginine)
- Active autoimmune neurological conditions (theoretical concern — no data)
- Children and adolescents (not studied)
Drug Interactions
- Melatonin supplements — potential additive effects on sleep; monitor for excessive sedation
- Sedatives and benzodiazepines — theoretical additive CNS effects
- Immunosuppressants — unknown interaction potential given proposed gene-regulatory activity
- No formal drug interaction studies have been conducted
Storage & Stability
Molecular Profile
Related Peptides
References
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease (Molecules 2021)PubMed 33396470
- Pinealon Protects the Rat Offspring from Prenatal Hyperhomocysteinemia (Int J Clin Exp Med 2012)PubMed 22567179
- Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease (Bull Exp Biol Med 2017)PubMed 28853087
- Peptides of Pineal Gland and Thymus Prolong Human Life (Neuro Endocrinol Lett 2003)PubMed 14523363
- Neuroprotective Effects of Peptide Bioregulators in People of Various Age (Adv Gerontol 2013)PubMed 24738258